Skip to content
OpenCapital
Get started

Prime Medicine PRME Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number at other companies

Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
——
Precigen logo
PrecigenPGEN
——
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
——

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Market cap$574.36M+111%
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%—

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's share-based compensation arrangement by share-based payment award, options, outstanding, number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's share-based compensation arrangement by share-based payment award, options, outstanding, number?
Prime Medicine (PRME) reported share-based compensation arrangement by share-based payment award, options, outstanding, number of $20.88M in Q1 2026.
How has Prime Medicine's share-based compensation arrangement by share-based payment award, options, outstanding, number changed year-over-year?
Prime Medicine's share-based compensation arrangement by share-based payment award, options, outstanding, number increased by 36.2% year-over-year, from $15.33M to $20.88M.
What is the long-term trend for Prime Medicine's share-based compensation arrangement by share-based payment award, options, outstanding, number?
Over 4 years (2021 to 2025), Prime Medicine's share-based compensation arrangement by share-based payment award, options, outstanding, number has grown at a 51.1% compound annual growth rate (CAGR), from $3M to $15.64M.